Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 880 participants.
Also called NCT01538446
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 880 participants
- Registry
-
NCT01538446
-
- Main results
- Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial
- Other papers using this trial's data
- Bleeding in the Elderly: Risk Factors and Impact on Clinical Outcomes After an Acute Coronary Syndrome, a Sub-study of the Randomized ANTARCTIC Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- France
- Registry status
- Completed
Technical summary
Registry record NCT01538446. Randomized; no masking; primary purpose treatment. Start 2012-03 (registry gives no type); primary completion 2016-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel
- Acronym
- ANTARCTIC
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- Modification of Prasugrel based on a biological assay
- Intervention (Drug)
- prasugrel / clopidogrel
- Intervention (Device)
- Verify Now
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Collaborator
- Eli Lilly and Company
- Collaborator
- Daiichi Sankyo
- Collaborator
- Allies in Cardiovascular Trials Initiatives and Organized
- Collaborator
- Accumetrics, Inc.
- Collaborator
- Stentys
Record details
- Record id
cardio:ct-nct01538446- Content hash
4cd7c55c7afd045d15cc6d0445fbd7e1cfb3de969a9d3a46579f9d0322b58b0f